Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (1y) (2012 - 2026)
Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 333.00 |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -469.00 |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 8.00 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 220.00 |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 802.00 |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 340.00 |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 573.00 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -1,932.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 340.00 |
| Mar 31, 2026 | 448.00 |
| Dec 31, 2025 | -158.00 |
| Sep 30, 2025 | -336.00 |
| Jun 30, 2025 | -267.00 |
| Mar 31, 2025 | -197.00 |
| Dec 31, 2024 | 781.00 |
| Sep 30, 2024 | 935.00 |
| Jun 30, 2024 | 1,002.00 |
| Mar 31, 2024 | 1,091.00 |
| Dec 31, 2023 | -401.00 |
| Sep 30, 2023 | 313.00 |
| Jun 30, 2023 | 422.00 |
| Mar 31, 2023 | 262.00 |
| Dec 31, 2022 | 879.00 |
| Sep 30, 2022 | -508.00 |
| Jun 30, 2022 | -353.00 |
| Mar 31, 2022 | -448.00 |
| Dec 31, 2021 | -568.00 |
| Sep 30, 2021 | -363.00 |